drugset / Trial / NCT01656252

Trial of Eltrombopag During Consolidation Therapy in Adults With AML in Complete Remission

NCT01656252

RandomizedParallel-groupTriple-blindTreatment

Summary

Patients with Acute Myeloid Leukemia (AML) in complete remission will receive eltrombopag while undergoing consolidation chemotherapy with high-dose cytarabine. Eltrombopag may help increase the number of platelets during chemotherapy and may help prevent the risk of bleeding. Phase I will study the side effects, best dose and platelet effects of eltrombopag when given with consolidation chemotherapy. After the maximum safe and tolerated dose and schedule is found in Phase I, the study will proceed to Phase II. Phase II will confirm the dose and schedule of eltrombopag identified in Phase I that can increase platelet counts in patients receiving consolidation therapy.

Timeline

Start
2012-07
Primary completion
2016-03
Completion
2016-03

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Eltrombopag Small molecule 150 mg Oral
Background Cytarabine Small molecule 1.5 g Intravenous
Background Cytarabine Small molecule 3 g Intravenous